Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a β thalassemic mouse: A model for human therapy

Blood

Volumn 87, Issue 3, 1996, Pages 1188-1195

  De Franceschi, Lucia ^b   Rouyer Fessard, Philippe ^b   Alper, Seth L ^b   Jouault, Helene ^b   Brugnara, Carlo ^a   Beuzard, Yves ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOTRIMAZOLE; ERYTHROPOIETIN; HYDROXYUREA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BETA THALASSEMIA; CELL DENSITY; CELL SURVIVAL; CONTROLLED STUDY; DEHYDRATION; DRUG EFFICACY; HEMATOCRIT; INTRAGASTRIC DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MEAN CORPUSCULAR HEMOGLOBIN; MOUSE; NONHUMAN; POTASSIUM CELL LEVEL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030063536     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.3.1188.bloodjournal8731188     Document Type: Article

References (53)

1. McDonagh KT, Nienhuis AW: The thalassemias, in Nathan DG, Oski FA, (eds): Hematology of Infancy and Childhood. Philadelphia, PA, Saunders, 1993, p 783
2. Shinar E, Rachmilewitz EA: Oxidative denaturation of red cells in thalassemia. Semin Hematol 27:70, 1990
3. Rachmilewitz EA, Lubin BH, Shohet S: Lipid membrane oxidation in β thal major. Blood 47:495, 1976
4. Rouyer-Fessard P, Garel MC, Domenget C, Guetarni D, Bachir D, Colonna P, Beuzard Y: A study of membrane protein defects and α hemoglobin chains of red blood cells in human b thalassemia. J Biol Chem 264:19092, 1989
5. Advani R, Sorenson S, Shinar E, Lande W, Rachmilewitz E, Schrier SL: Characterization and comparison of red blood cell membrane damage in severe human α and β thalassemia. Blood 79:1058, 1992
6. Olivieri O, De Franceschi L, Capellini MD, Girelli D, Corrocher R, Brugnara C: Oxidative damage and erythrocyte membrane transport abnormalities in thalassemias. Blood 84:315, 1994
7. Leroy-Viard K, Royer-Fessard P, Beuzard Y: Improvement of mouse β thalassemia by recombinant human erythropoietin. Blood 78:1596, 1991
8. Sauvage C, Rouyer-Fessard P, Beuzard Y: Improvement of mouse β thalassemia by hydroxyurea. Br J Haematol 84:492, 1993
9. Alter BP, Campbell AS, Holland JG, Friend C: Increased mouse minor hemoglobin during erythroid stress: A model for hemoglobin regulation. Exp Hematol 10:754, 1982
10. Curcio MJ, Kantoff P, Schafer MP, Anderson WF, Safer B: Compensatory increase in levels of β minor globin in murine β thalassemia is under translational control J Biol Chem 261:16,126, 1986
11. Popp RA, Stratton LP, Hawley DK, Tierney EC, Hirsch GP: Altered concentrations of parental type hemoglobins in alpha thalassemic mice. Genetics 83:858, 1976
12. Johnson FM, Lewis SE: Electrophoretically detected germinal mutations induced in the mouse by ethylnitrosourea. Proc Natl Acad Sci USA 78:3138, 1981
13. Skow LC, Burkhart BA, Johnson FM, Popp RA, Popp DM, Goldberg SR, Anderson WF, Barnett LB, Lewis SE: A mouse model for β thalassemia. Cell 34:1043, 1982
14. Schrier SL, Rachmilewitz EA, Mohandas N: Cellular and membrane properties of alpha and beta thalassemic erythrocytes are different: Implications for differences in clinical manifestations. Blood 74:2194, 1989
15. Gunn RB, Silvers DN, Rosse WF: Potassium permeability in β-thalassemia minor red blood cells. J Clin Invest 51:1043, 1972
16. Vettore L, Falezza GC, Cetto GL, De Matteis MC: Cation content and membrane deformability of heterozygous β thalassaemic red blood cells. Br J Haematol 27:429, 1974
17. Brugnara C, Bunn HF, Tosteson DC: Regulation of erythrocyte cation and water content in sickle cell anemia. Science 232:388, 1986
18. Canessa M, Spalvins A, Nagel RL: Volume dependent and NEM stimulated K/Cl cotransport is elevated in SS, SC and CC human red cells. FEBS Lett 200:197, 1986
19. Olivieri O, Vitoux D, Galacteros F, Bachir D, Bloquit Y, Beuzard Y, Brugnara C: Hemoglobin variants and activity of the K/ Cl cotransport system in human erythrocytes. Blood 79:793, 1992
20. Gardos G: The function of calcium in the potassium permeability of human erythrocytes. Biochem Biophys Acta 30:653, 1958
21. Bookchin RM, Ortiz OE, Lew VL: Evidence for a direct reticulocyte origin of dense red cells in sickle cell anemia. J Clin Invest 87:113, 1991
22. Schrier SL, Mohandas N: Globin-chain specificity of oxidation-induced changes in red blood cell membrane properties. Blood 79:1586, 1992
23. + channels by cytochrome P-450 inhibitors. J Biol Chem 267:11789, 1992
24. + channel: The imidazole ring is not required for inhibitory activity. J Pharmacol Exp Ther 273:266, 1995
25. + transport and reverses erythrocyte dehydration in transgenic SAD mice. J Clin Invest 93:1670, 1994
26. + transport and cell dehydration in sickle cell erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest 92:520, 1993
27. Brugnara C, Gee B, Armsby C, Kurth S, Sakamoto M, Rifai N, Alper S, Platt O: Inhibition of Gardos channel and red cell dehydration by oral administration of clotrimazole in sickle cell disease. Blood 84:220a, 1994
28. Chinn-Yee I, Keeney M, Lohmann RC: Flow cytometric reticulocyte analysis using thiazole orange; clinical experience and technical limitations. Clin Lab Haematol 13:177, 1991
29. Davis BH, Bigelow NC: Flow cytometric reticulocyte quantification using thiazole orange provides clinically useful reticulocyte maturity index. Arch Pathol Lab Med 113:684, 1989
30. Danon D, Marikovsky Y: Determination of density distribution of red cell population. J Lab Clin Med 64:668, 1964
31. Godfay K: Comparing the means of several groups. New Engl J Med 313:1450, 1985
32. Brugnara C, Kopin A, Bunn HF, Tosteson DC: Regulation of cation content and cell volume in erythrocytes from patients with homozygous hemoglobin C disease. J Clin Invest 75:1608, 1985
33. + channel in human erythrocytes by mechanical stress. Biochim Biphys Acta 1107:314, 1992
34. Hebbel RP, Narla M. Reversible deformation-dependent erythrocyte cation leak. Extreme sensitivity conferred by minimal peroxidation. Biophys J 60:712, 1991
35. Nathan, DG, Gunn RB: Thalassemia: The consequence of unbalanced hemoglobin synthesis Am J Med 41:815, 1966
36. Wiley J: Increased erythrocyte cation permeability in thalassemia and conditions of bone marrow stress J Clin Invest 67:917, 1981
37. Bookchin RM, Ortiz OE, Shalev O, Tsurel S, Rachmilewitz EA, Hockaday A, Lew VL: Calcium transport and ultrastructure of red cells in β-thalassemia intermedia Blood 72:1602, 1988
38. 2+ concentration are not impaired in β-thalassemic and hemoglobin C eryhthrocytes. Blood 70:804, 1987
39. Goldberg M, Brugnara C, Dover GJ, Shapira L, Charache S, Bunn HF: Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 323:366, 1990
40. Rodgers G, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW: Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 328:73, 1993
41. Cozma G, Cozma MC, Mattes U. Beneficial effect of recombinant human erythropoietin in beta thalassemia patients on dialysis. Nephrol Dial Transplant 7:82, 1992
42. Olivieri NF, Freedman MH, Perrine SP, Dover GJ, Sheridan B, Essentine DL, Nagel RL: Trial of recombinant human erythropoietin: Three patients with thalassemia intermedia. Blood 80:3258, 1992
43. Aker M, Dover G, Schrier S, Rachmilewitz EA: Sustained increase in hemoglobin, Hct & RBC following long term administration of recombinant human erythropoietin to patients with β thalassemia intermedia. Blood 82:358a, 1993
44. Cohen AR, Martin MB, Schwartz E: Hydroxyurea therapy in thalassemia intermedia. Proceedings of "New Trends in Therapy for Hemoglobinopathies and Thalassemias," INSERM, Paris, France, 1994, III-8
45. Aker M, Dover G, Schrier S, Rachmilewitz ES: Combination of erythropoietin and hydroxyurea results in improved quality and quantity of RBC in 7 patients with thalassemia intermedia. Proceedings of "New Trends in Therapy for Hemoglobinopathies and Thalassemias," INSERM, Paris, France, 1994, III-10
46. Villeval JL, Rouyer-Fessard P, Blumenfeld N, Henri A, Vainchenker W, Beuzard Y: Retrovirus-mediated transfer of the erythropoietin gene in hematopoietic cells improves the erythrocyte phenotype in murine β thalassemia. Blood 84:928, 1994
47. Sawyer PR, Brogden RN, Pinder RM, Speight TM, Avery GS: Clotrimazole: A review of its antifungal activity and therapeutic efficacy. Drugs 9:424, 1975
48. Matsuura Y, Kotani E, Iio T: Structure-activity relationship in the induction of hepatic microsomal cytochrome P450 by clotrimazole and its structurally related compounds in rats. Biochem Pharmacol 41:1949 1991
49. Capdevila J, Gil L, Orellana M, Marnett LJ, Mason JI, Yadagiri P, Falk JR: Inhibitors of cytochrome P-450 dependent arachidonic acid metabolism. Arch Biochem Biophys 261:257, 1988
50. Montera M, Alvarez J, Garcia-Sancho J: Agonist-induced Ca++ influx in human neutrophils is secondary to the emptying of intracellular calcium stores. Biochem J 277:73, 1991
51. Villalobos C, Fonteriz R, Lopez M, Garcia AG, Garcia-Sancho J: Inhibition of voltage-gated Ca++ entry into GH3 and chromaffin cells by imidazole antimycotics and other cytochrome P450 blockers FASEB J 6:2742, 1992
52. Rittenhouse A, Brugnara C, Alper SL: Clotrimazole, a blocker of calcium-activated K+ channels. Biophys J 66:A209, 1994 (abstr)
53. Benzaquen L, Brugnara C, Byers HR, Gattoni-Celli S, Halperin JA: Clotrimazole inhibits cell proliferation in vitro and in vivo. Nature Med 1:534, 1995